Accessibility Menu
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. logo

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd.(SEHK) 1349

Market CapHK$2.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)+283%
5 Year-40%
1 Year-29%
1 Month+4%
HK$2.52
-0.59%
-0.02Today
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. last closing stock price
MetricPriceDate
Last closeHKD 2.522026-08-31
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.56%HKD 2.562026-08-24
1 month+4.13%HKD 2.422026-07-31
3 month+3.28%HKD 2.442026-06-02
Year to date-9.35%HKD 2.782025-12-31
1 year-29.41%HKD 3.572025-08-29
3 year+0.4%HKD 2.512023-08-31
5 year-40%HKD 4.202021-09-01
Since inception+282.81%HKD 0.662002-08-13

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. Financials at a Glance

Market Cap

HK$2.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥664.95M

Net Income (TTM)

-CN¥124.10M

EPS (TTM)

-HK$0.13

P/E Ratio

-19.23

Dividend

HK$0.00

Beta (Volatility)

0.00 (Low)

Price

HK$2.52

Volume

1,068,000

Open

HK$2.52

Previous Close

HK$2.54

Daily Range

HK$2.51 - HK$2.52

52-Week Range

HK$2.20 - HK$4.05

Estimated Earnings Date

Oct 22, 2026

1349 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. is a leading biopharmaceutical company focused on the research, development, production, and commercialization of innovative drug therapies. The company specializes in antibody-drug conjugates (ADCs) and utilizes advanced technologies to address various medical conditions.

Products and Services
  • Antibody-drug conjugates for oncology treatments
  • Photodynamic therapy products for skin conditions
  • Oral solid preparations for autoimmune disorders
Growth Outlook
  • Strong pipeline with multiple ADCs in clinical trials
  • Expansion into international markets for biopharmaceuticals
  • Investment in R&D to enhance product offerings
Financial Highlights
  • Recent quarterly revenue of 149 million CNY, showing growth
  • Cash and short-term investments totaling 1.13 billion CNY
  • Net income of 7.7 million CNY in the latest quarter
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has established itself as a significant player in the biopharmaceutical industry, leveraging its expertise in genetic engineering and nanotechnology. The company is actively engaged in developing innovative therapies, particularly in oncology, with several products in various stages of clinical trials. The robust pipeline and commitment to research and development position the company for future growth, particularly as it seeks to expand its market presence internationally. Recent financial performance indicates a positive trajectory, with increasing revenue and substantial cash reserves, providing a solid foundation for ongoing operations and strategic initiatives.
AI Generated • Aug 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

876

CEO

Da Jun Zhao, MBA

Website

www.fd-zj.com

Headquarters

Shanghai, SH 201210, CN

1349 Financials

Key Financial Metrics (TTM)

Gross Margin

99.50%

Operating Margin

-21.46%

Net Income Margin

-18.90%

Return on Equity

-5.84%

Return on Capital

-7.29%

Return on Assets

-5.23%

Earnings Yield

-5.20%

Dividend Yield

0.00%

Payout Ratio

-24.63%

Stock Overview

Market Cap

HK$2.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.04B

Volume

1.07M

Avg. Volume

2.60M

Financials (TTM)

Gross Profit

CN¥580.76M

Operating Income

-CN¥129.58M

EBITDA

-CN¥99.26M

Operating Cash Flow

CN¥166.02M

Capital Expenditure

-CN¥23.20M

Free Cash Flow

CN¥142.93M

Cash & ST Invst.

CN¥1.22B

Total Debt

CN¥11.99M

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. Performance Analysis

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 1,193,745,681-12.8%
20232023-12-31CNY 937,202,033-21.5%
20242024-12-31CNY 765,475,718-18.3%
20252025-12-31CNY 739,111,878-3.4%
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-23.4%
Q42025-12-31-17.5%
Q12026-03-3112.3%
Q22026-06-3049.1%
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.16-36.8%
20232023-12-31CNY 0.12-25.4%
20242024-12-31CNY 0.04-64.2%
20252025-12-31CNY -0.16N/A
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-820.7%
Q42025-12-31-522.0%
Q12026-03-31105.7%
Q22026-06-30278.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥222.23M

+5.7%

Gross Profit

CN¥191.13M

+2.7%

Gross Margin

86.01%

N/A

Market Cap

HK$2.63BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$3.00M

N/A

Employees

876

N/A

Net Income

CN¥29.06M

+852.8%

EBITDA

CN¥45.50M

+435.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥1.22B

+10.5%

Total Debt

CN¥11.99M

-30.5%

Accounts Receivable

CN¥286.47M

-35.0%

Inventory

CN¥28.18M

-17.9%

Long Term Debt

CN¥6.54M

-44.9%

Short Term Debt

CN¥5.44M

-51.7%

Return on Assets

-5.23%

N/A

Return on Invested Capital

-6.58%

N/A

Free Cash Flow

CN¥85.46M

+103.5%

Operating Cash Flow

CN¥88.78M

+60.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 1349

What is the current price of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd.?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. is trading at HK$2.52 per share.

What is the 52-week range for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd.?

Over the past 52 weeks, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. has traded between HK$2.20 and HK$4.05.

How much debt does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. have?

As of the most recent reporting period, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. reported total debt of CN¥13.85M.

How much cash does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. have on hand?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. reported CN¥1.41B in cash and cash equivalents in its most recent financial results.

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd.’s dividend yield?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical,Ltd. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services